Literature DB >> 28988432

Impact of flow, gradient, and left ventricular function on outcomes after transcatheter aortic valve replacement.

Edward T Carreras1, Tsuyoshi Kaneko2, Fernando Ramirez-Del Val2, Marc P Pelletier2, Piotr S Sobieszczyk1, Deepak L Bhatt1, Pinak B Shah1.   

Abstract

OBJECTIVES: To assess the impact of low flow with and without preserved left ventricular ejection fraction (LVEF) on outcomes after transcatheter aortic valve replacement (TAVR).
BACKGROUND: Prior studies have shown that patients with low flow, AVG, and LVEF have worse outcomes after TAVR. It is unclear whether low AVG and LVEF remain prognostic after adjusting for flow, and how the outcomes of patients with low flow with and without preserved LVEF compare after TAVR. The goal of this study was to provide insight into these open questions.
METHODS: Data from 340 TAVR patients at Brigham and Women's Hospital from 2011 through 2015 were analyzed. Low flow was defined as stroke volume index (SVI) ≤35 mL/m2 , low AVG as mean gradient < 40 mmHg, and reduced LVEF as < 50%.
RESULTS: Low flow was present in 96 (28.2%) patients, 48 (50.0%) of whom also had reduced LVEF. At 1 year, low flow was associated with increased mortality (21.9 vs 7.4%; P = 0.0002) and heart failure (HF) (20.8 vs 5.3%; P = 0.0113). Among patients with low flow, those with preserved LVEF had increased mortality (HR 5.17, 95% CI 2.73-9.80; P < 0.001) and HF (HR 7.69, 95% CI 3.86-15.31; P < 0.001). After adjusting for clinical factors, patients with low flow had increased mortality (HR 6.51, 95% CI 2.98-14.22; P < 0.001) and HF (HR 5.52, 95% CI 2.34-12.98; P < 0.001), while neither low AVG nor low LVEF were associated with increases in mortality or HF.
CONCLUSIONS: In patients undergoing TAVR, low flow was an independent predictor of 1-year mortality and HF, and a stronger predictor than either low AVG or LVEF. Patients with low flow and preserved EF had increased mortality and HF at 1-year, while those with low flow and reduced EF had outcomes similar to patients with normal flow.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  Aortic stenosis; Stroke volume; TAVR

Mesh:

Year:  2017        PMID: 28988432      PMCID: PMC5849510          DOI: 10.1002/ccd.27347

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  26 in total

1.  Transcatheter versus surgical aortic-valve replacement in high-risk patients.

Authors:  Craig R Smith; Martin B Leon; Michael J Mack; D Craig Miller; Jeffrey W Moses; Lars G Svensson; E Murat Tuzcu; John G Webb; Gregory P Fontana; Raj R Makkar; Mathew Williams; Todd Dewey; Samir Kapadia; Vasilis Babaliaros; Vinod H Thourani; Paul Corso; Augusto D Pichard; Joseph E Bavaria; Howard C Herrmann; Jodi J Akin; William N Anderson; Duolao Wang; Stuart J Pocock
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

2.  2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: Document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC).

Authors:  Raimund Erbel; Victor Aboyans; Catherine Boileau; Eduardo Bossone; Roberto Di Bartolomeo; Holger Eggebrecht; Arturo Evangelista; Volkmar Falk; Herbert Frank; Oliver Gaemperli; Martin Grabenwöger; Axel Haverich; Bernard Iung; Athanasios John Manolis; Folkert Meijboom; Christoph A Nienaber; Marco Roffi; Hervé Rousseau; Udo Sechtem; Per Anton Sirnes; Regula S von Allmen; Christiaan J M Vrints
Journal:  Eur Heart J       Date:  2014-08-29       Impact factor: 29.983

3.  2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Rick A Nishimura; Catherine M Otto; Robert O Bonow; Blase A Carabello; John P Erwin; Robert A Guyton; Patrick T O'Gara; Carlos E Ruiz; Nikolaos J Skubas; Paul Sorajja; Thoralf M Sundt; James D Thomas
Journal:  Circulation       Date:  2014-03-03       Impact factor: 29.690

Review 4.  Current perspectives on cardiac amyloidosis.

Authors:  Jian Guan; Shikha Mishra; Rodney H Falk; Ronglih Liao
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-11-04       Impact factor: 4.733

5.  TAVI for low-flow, low-gradient severe aortic stenosis with preserved or reduced ejection fraction: a subgroup analysis from the German Aortic Valve Registry (GARY).

Authors:  Alexander Lauten; Hans R Figulla; Helge Möllmann; David Holzhey; Joachim Kötting; Andreas Beckmann; Christof Veit; Jochen Cremer; Karl-Heinz Kuck; Rüdiger Lange; Ralf Zahn; Stefan Sack; Gerhard Schuler; Thomas Walther; Friedhelm Beyersdorf; Michael Böhm; Gerd Heusch; Thomas Meinertz; Till Neumann; Armin Welz; Friedrich W Mohr; Christian W Hamm
Journal:  EuroIntervention       Date:  2014-11       Impact factor: 6.534

6.  Aortic valve replacement for aortic stenosis in patients with left ventricular dysfunction.

Authors:  Michael E Halkos; Edward P Chen; Eric L Sarin; Patrick Kilgo; Vinod H Thourani; Omar M Lattouf; J David Vega; Cullen D Morris; Thomas Vassiliades; William A Cooper; Robert A Guyton; John D Puskas
Journal:  Ann Thorac Surg       Date:  2009-09       Impact factor: 4.330

7.  Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.

Authors:  Esther González-López; Maria Gallego-Delgado; Gonzalo Guzzo-Merello; F Javier de Haro-Del Moral; Marta Cobo-Marcos; Carolina Robles; Belén Bornstein; Clara Salas; Enrique Lara-Pezzi; Luis Alonso-Pulpon; Pablo Garcia-Pavia
Journal:  Eur Heart J       Date:  2015-07-28       Impact factor: 29.983

8.  Low-flow aortic stenosis in asymptomatic patients: valvular-arterial impedance and systolic function from the SEAS Substudy.

Authors:  Dana Cramariuc; Giovanni Cioffi; Ashild E Rieck; Richard B Devereux; Eva M Staal; Simon Ray; Kristian Wachtell; Eva Gerdts
Journal:  JACC Cardiovasc Imaging       Date:  2009-04

9.  Predictors of mortality and outcomes of therapy in low-flow severe aortic stenosis: a Placement of Aortic Transcatheter Valves (PARTNER) trial analysis.

Authors:  Howard C Herrmann; Philippe Pibarot; Irene Hueter; Zachary M Gertz; William J Stewart; Samir Kapadia; E Murat Tuzcu; Vasilis Babaliaros; Vinod Thourani; Wilson Y Szeto; Joseph E Bavaria; Susheel Kodali; Rebecca T Hahn; Mathew Williams; D Craig Miller; Pamela S Douglas; Martin B Leon
Journal:  Circulation       Date:  2013-05-09       Impact factor: 29.690

10.  Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.

Authors:  Martin B Leon; Craig R Smith; Michael J Mack; Raj R Makkar; Lars G Svensson; Susheel K Kodali; Vinod H Thourani; E Murat Tuzcu; D Craig Miller; Howard C Herrmann; Darshan Doshi; David J Cohen; Augusto D Pichard; Samir Kapadia; Todd Dewey; Vasilis Babaliaros; Wilson Y Szeto; Mathew R Williams; Dean Kereiakes; Alan Zajarias; Kevin L Greason; Brian K Whisenant; Robert W Hodson; Jeffrey W Moses; Alfredo Trento; David L Brown; William F Fearon; Philippe Pibarot; Rebecca T Hahn; Wael A Jaber; William N Anderson; Maria C Alu; John G Webb
Journal:  N Engl J Med       Date:  2016-04-02       Impact factor: 91.245

View more
  3 in total

Review 1.  Transcatheter valve interventions in heart failure: new answers to old questions.

Authors:  Marijana Tadic; Cesare Cuspidi
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

Review 2.  Transcatheter aortic valve replacement in patients with severe aortic stenosis and heart failure.

Authors:  Chirag Bavishi; Dhaval Kolte; Paul C Gordon; J Dawn Abbott
Journal:  Heart Fail Rev       Date:  2018-11       Impact factor: 4.214

3.  Possible predictive role of electrical risk score on transcatheter aortic valve replacement outcomes in older patients: preliminary data.

Authors:  Gianfranco Piccirillo; Federica Moscucci; Fabiola Mastropietri; Claudia Di Iorio; Marco Valerio Mariani; Marcella Fabietti; Gaetana M Stricchiola; Ilaria Parrotta; Gennaro Sardella; Massimo Mancone; Damiano Magrì
Journal:  Clin Interv Aging       Date:  2018-09-11       Impact factor: 4.458

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.